Table 4.

Comparison by age, ≥75 years old vs < 75 years old.

Age	<75	≧75
n	31	24
Median age (years)	67.0	77.5
Reduction of drug (cases, %)	15, (48.4)	19, (79.2)
Median cabazitaxel dose (mg/m2)	25	20
Number of treatments discontinued owing to adverse events and deterioration of general condition (number, %)	3, (9.7)	10, (41.3)
Adverse events ≧ G3 (number)	Thrombocytopenia G3 (2), G4 (1), Anemia G3 (2), Diarrhea G5 (1)	All adverse events Thrombocytopenia G3 (1), Anorexia G3 (3), Vomiting G3 (2), Fatigue G3 (1), FNG3 (7), FNG4 (2), Pneumonia G3 (1), Gastrointestinal perforation G4 (1), Sepsis G4 (1). 25 mg/m2(n = 5) Thrombocytopenia G3 (1), Anorexia G3 (3), Vomiting G3 (2), Gastrointestinal perforation G4 (1), FNG3 (3)

FN, febrile neutropenia. To make it easier to see that the cabazitaxel dose is changing is given in bold.